Pediatric Ependymoma: A Proteomics Perspective

Tsangaris, George Th.; Papathanasiou, Chrissa; Adamopoulos, Panagiotis G.; Scorilas, Andreas; Vorgias, Constantinos E.; Prodromou, Neofytos; Stathopoulou, Foteini Tzortzatou; Stravopodis, Dimitrios J.; Anagnostopoulos, Athanasios K.

doi:10.21873/cgp.20025

Cited by 9 publications

(5 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Protein tryptic digestion and TMT reagent labeling. For digestion, 40 μg of depleted plasma proteins from each sample were reduced by 10mM Tris-(2-carboxy-ethyl) phosphine (TCEP) at 56˚C for 1 h, alkylated by addition of 20 mM iodoacetamide for 1h at room temperature in the dark and treated by trypsin protease (Promega, Madison, WI, USA) at a ratio of 1:100 at 37˚C over-night to generate proteolytic peptides (9). After trypsin digestion, peptides were lyophilized to near dryness.…”

Section: Methodsmentioning

confidence: 99%

Quantitative Comparative Proteomics Reveals Candidate Biomarkers for the Early Prediction of Gestational Diabetes Mellitus: A Preliminary Study

Mavreli

Evangelinakis

Παπαντωνίου

et al. 2020

In Vivo

View full text Add to dashboard Cite

Aim: To identify differentially expressed proteins (DEPs) in 1 st trimester maternal plasma between pregnant women at risk for gestational diabetes mellitus (GDM) and uncomplicated controls. Materials and Methods: Firsttrimester plasma from five women who developed GDM and five from non-diabetic ones were analyzed using isobaric tag for relative and absolute quantitation -labeled proteomics. Enzyme-linked immunosorbent assay was further applied in an independent cohort of 25 GDM cases and 25 controls for verification. Results: Prenylcysteine oxidase 1 (PCYOX1), beta-ala-his dipeptidase (CNDP1), extracellular matrix protein 1 (ECM1), basement membrane-specific heparan sulfate proteoglycan core protein (HSPG2), thrombospondin-4 (TSP-4) demonstrated significant differences in expression between the two groups (p<0.05). DEPs are mainly associated with complement and coagulation cascades. Conclusion: The reported plasma proteomic changes represent potential biomarkers for the early identification of women at risk for GDM. Future studies using larger and more diverse cohorts are necessary to assess the clinical utility of these findings.

show abstract

Section: Methodsmentioning

confidence: 99%

Quantitative Comparative Proteomics Reveals Candidate Biomarkers for the Early Prediction of Gestational Diabetes Mellitus: A Preliminary Study

Mavreli

Evangelinakis

Παπαντωνίου

et al. 2020

In Vivo

View full text Add to dashboard Cite

show abstract

“…Some studies [17] suggest that tumors with combined 1q gain and TNC expression had the poorest outcomes, while tumors without 1q gain and TNC expression had the most favorable outcomes, and TNC-positive 1q non-gained cases had an intermediate outcome. Recently, some promising advancements of potential prognostic markers in molecular neuropathology have been made [18], which might contribute to a better outcome. In the future there will be more convincing markers relating to prognosis.…”

Section: Discussionmentioning

confidence: 99%

Clinical Characteristics and Prognostic Factors of Treatment in Pediatric Posterior Cranial Fossa Ependymoma

Agazzi

et al. 2019

Pediatr Neurosurg

View full text Add to dashboard Cite

Objective: The purpose of this study was to explore the clinical features and risk factors of outcomes in pediatric posterior cranial fossa ependymoma. We aim to provide evidence-based recommendations for the improvement of prognoses. Patients and Methods: The clinical data, treatment modalities, approaches performed, recurrence rates and times, as well as the outcomes of 94 cases were analyzed retrospectively. The characters of neuroimaging were further studied. Results: In data from the most recent follow-up, 27 cases had tumor recurrence. The time for tumor recurrence was 13.7 ± 7.7 months. The estimated overall survival and progression-free survival, based on Kaplan-Meier analysis, was 42.2 ± 2.9 months and 38.7 ± 3.4 months, respectively. Univariate analysis showed that being free of recurrence is closely related to the high tumor sphericity (p = 0.018), homogeneity of tumor texture (p = 0.001), and gross total resection (GTR; p < 0.001). Mortality is linked to low sphericity (p = 0.017) and brain stem edema (p = 0.005). Cerebellar mutism is correlated with posterosuperior compression of the 4th ventricle roof by the tumor. The incidence rate of cerebellar ataxia, cerebellar mutism, and cerebellar dysarthria is related to the rostral extension of the tumor within the 4th ventricle. The recurrence rate is higher in subtotal resection (STR) than in GTR, and the difference is significant (p < 0.001). Although there is no significant difference between the recurrence rates in the three types, an earlier recurrence is prone with tumors located in the paramidline-lateral compared to the midline (p = 0.021) and paramidline-medial areas (p = 0.042). Conclusions: Based on our data, GTR is indicated as the most optimal choice. Recurrence is linked to lower tumor sphericity, inhomogeneous tumor texture, and STR/partial resection. Tumor located on the lateral side might be prone for an early recurrence.

show abstract

“…It can detect sarcoma-specific fusion transcripts in a single reaction with 100% concordance to RT-PCR [ 133 ]. In the proteomic analysis of pediatric ependymoma using high-resolution mass spectrometry, similarities with other pediatric brain tumor entities, such as astrocytomas and medulloblastomas, have been revealed [ 134 ]. Table 1 summarizes examples of nanocarrier systems utilized in pediatric medicine.…”

Section: Pediatric Cancer Treatment and Researchmentioning

confidence: 99%

“…Pharmaceutics 2023, 15, x FOR PEER REVIEW 5 of 33 ric ependymoma using high-resolution mass spectrometry, similarities with other pediatric brain tumor entities, such as astrocytomas and medulloblastomas, have been revealed [134]. Table 1 summarizes examples of nanocarrier systems utilized in pediatric medicine.…”

Section: Pediatric Cancers In Generalmentioning

confidence: 99%

Exploring the Potential of Nanotechnology in Pediatric Healthcare: Advances, Challenges, and Future Directions

Omidian

Mfoafo

2023

Pharmaceutics

View full text Add to dashboard Cite

The utilization of nanotechnology has brought about notable advancements in the field of pediatric medicine, providing novel approaches for drug delivery, disease diagnosis, and tissue engineering. Nanotechnology involves the manipulation of materials at the nanoscale, resulting in improved drug effectiveness and decreased toxicity. Numerous nanosystems, including nanoparticles, nanocapsules, and nanotubes, have been explored for their therapeutic potential in addressing pediatric diseases such as HIV, leukemia, and neuroblastoma. Nanotechnology has also shown promise in enhancing disease diagnosis accuracy, drug availability, and overcoming the blood–brain barrier obstacle in treating medulloblastoma. It is important to acknowledge that while nanotechnology offers significant opportunities, there are inherent risks and limitations associated with the use of nanoparticles. This review provides a comprehensive summary of the existing literature on nanotechnology in pediatric medicine, highlighting its potential to revolutionize pediatric healthcare while also recognizing the challenges and limitations that need to be addressed.

show abstract

Pediatric Ependymoma: A Proteomics Perspective

Cited by 9 publications

References 38 publications

Quantitative Comparative Proteomics Reveals Candidate Biomarkers for the Early Prediction of Gestational Diabetes Mellitus: A Preliminary Study

Quantitative Comparative Proteomics Reveals Candidate Biomarkers for the Early Prediction of Gestational Diabetes Mellitus: A Preliminary Study

Clinical Characteristics and Prognostic Factors of Treatment in Pediatric Posterior Cranial Fossa Ependymoma

Exploring the Potential of Nanotechnology in Pediatric Healthcare: Advances, Challenges, and Future Directions

Contact Info

Product

Resources

About